Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KL590586 in Advanced Solid Tumors Carrying RET Fusion Or Mutant Genes
NCT05265091Phase 2Active, not recruiting
- Sponsor
- Kelun-Biotech
- Start
- Sep 2021
- Primary completion
- Dec 2026
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of a400 in solid tumor, non-small cell lung cancer (NSCLC), Medullary Thyroid Cancer (MTC), sponsored by Kelun-Biotech. Started Sep 2021; status: active, not recruiting.
02
Drugs
a400
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on NCT05265091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05265091.